New Lundbeck CEO Deborah Dunsire is turning to M&A to build the pipeline.
Early Monday the Danish biotech reported that Dunsire had agreed to pay $250 million cash to snag San Diego-based Abide Therapeutics, where researchers have been working on a cannabinoid platform for new drugs to treat brain diseases.
In addition to the cash, Lundbeck is reserving up to $150 million for milestones. And they’ll be keeping the San Diego base, designating it as a discovery center for Lundbeck.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription